Japanese Vote of Confidence for Quay Pharmaceuticals - CCRA

echinoidclapΒιοτεχνολογία

1 Δεκ 2012 (πριν από 4 χρόνια και 10 μήνες)

276 εμφανίσεις




RELEASE REF:

QP/2010/005


ISSUE DATE:

13 August 2010



JAPANESE VOTE OF CONFIDENCE FOR QUAY PHARMA’S SKILLS



Quay Pharma h
as been appointed by a leading Japanese pharmaceutical company to
handle the clinical trial
drug
manufacture of two NCEs for UK
trials. The contract
was
won in conjunction with Quay’s Japanese representative InterPharm Express.


The
appointment
is significant because this is

the first time that the Japanese company,
which has a strong focus on the development of innovative product
s to treat diseases in
the elderly, has outsourced clinical trials manufacture to a European company.


Quay was selected due to its responsiveness and ability to meet the tight timelines
specified by the customer as well as its strong partnership with In
terPharm Express,
which ensured a high level of local support in Japan.


Quay Pharma has established a high quality reputation for its specialist outsourcing
services including formulation development, novel drug delivery design, analytical
method developm
ent and clinical trial manufacture and packaging. The company has
recently moved to a new purpose
-
designed facility in Deeside, North Wales.

…./

As part of the
implemen
tation
of the new projects,
Quay
has purchased additional
manufacturing
equipment inclu
ding a
Quadro
Comil
®

cone mill
and
a specially
commissioned
,

bespoke V shell b
lender
,
made to the exact requirements

of the client
.

Matching the equipment that the client had used in Japan ensured that transfer of the
project from Japan to the UK went as s
moothly as possible

and also allowed the
flexibility of scale
-
up for future manufacturing needs.


“We are extremely proud to have been selected for these prestigious projects,”
comments Quay Pharma’s Chief Executive Mike Rubinstein.


“The Japanese pharmac
eutical indust
ry is renowned for its rigorous

quality

requirements
, and our appointment therefore reflects and underlines the extremely high
standards that characterise all our work.”


Ends



About Quay Pharma:

Quay
Pharma is a leading global provider of
c
ontract pharmaceutical R & D and clinical
trials manufacturing
, with clients including
small and large pharmaceutical an
d
biotechnology companies world
wide.

Quay’s extensive range of services includes
early
stage (pre
-
clinical) formulation development, nov
el drug delivery design, analytical
method

development, stability testing
,

and clinical trial manufacture and packaging of
new drug compounds.

The company offers a total contract service,
from
late pre
-
clinical,
manufacture of
f
irst
in man studies to the
end of phase II clinical trials. Quay
Pharma is MHRA licensed and FDA registered.


Ends



Caption:

Quay Pharma has been appointed by a leading Japanese pharmaceutical company to
handle the clinical trial drug manufacture of two NCEs for UK trials.



EDIT
ORIAL ENQUIRIES:



Bob Bushby/Simon Kinnear


Nielsen McAllister PR Limited



32 Friar Gate





Derby DE1 1BX




UK







Tel: 44 1332 293939



Fax: 44 1332 382202



Email:
info@nmpr.co.uk



www.nmpr.co.uk






SALES/READER ENQUIRIES:

Quay Pharma

Tel: 44 151 2039800

Fax: 44 151 3349977

Email: enquiries@quaypharma.com

www.quaypharma.com